Edit Module

Zoetis Earns License for Cytopoint Skin Therapy

The newly branded therapy, formally known as Canine Atopic Dermatitis Immunotherapeutic, is formulated to target and neutralize interleukin-31 (IL-31).


Published:

Zoetis

Apoquel, say hello to your baby brother Cytopoint.

Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”

If the indication sounds familiar, it may be because Cytopoint earned a conditional license in August 2015, when it was known as Canine Atopic Dermatitis Immunotherapeutic. Cytopoint is injected every four to eight weeks.

The newly branded therapy is formulated to target and neutralize interleukin-31 (IL-31). The atopic dermatitis drug Apoquel (oclacitinib tablet) is designed to quickly rid dogs of the urge to itch.

Edit Module
Edit ModuleShow Tags

Archive »Read More

The Gonadectomy Controversy

Exploring the available data, making the case for more information and weighing the risks with pet owners.

Is it a Medical Problem or a Behavior Problem?

Manage tricky behavior cases by determining medical factors, championing client education and knowing when to refer issues beyond your clinic’s scope.

The Immunity Challenge: Vaccines and Pets

The latest about vaccines.
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module